Dai JW, Xing YX, Sun NZ. Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions. World J Gastrointest Surg 2025; 17(8): 108160 [DOI: 10.4240/wjgs.v17.i8.108160]
Corresponding Author of This Article
Nian-Zhe Sun, MD, PhD, Department of Orthopedics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha 410008, Hunan Province, China. sunnzh201921@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Aug 27, 2025; 17(8): 108160 Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.108160
Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions
Jin-Wei Dai, Yi-Xuan Xing, Nian-Zhe Sun
Jin-Wei Dai, Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Jin-Wei Dai, Yi-Xuan Xing, Nian-Zhe Sun, National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Yi-Xuan Xing, Department of Emergency, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Nian-Zhe Sun, Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Co-corresponding authors: Yi-Xuan Xing and Nian-Zhe Sun.
Author contributions: Dai JW wrote the first draft, developed the main ideas, and led revisions; Sun NZ and Xing YX provided critical feedback, improved the structure, and added key examples, they contributed equally to this manuscript as co-corresponding authors.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nian-Zhe Sun, MD, PhD, Department of Orthopedics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha 410008, Hunan Province, China. sunnzh201921@sina.com
Received: April 7, 2025 Revised: April 24, 2025 Accepted: June 20, 2025 Published online: August 27, 2025 Processing time: 141 Days and 1.2 Hours
Core Tip
Core Tip: Whether patients with stage II gallbladder cancer should routinely receive adjuvant chemotherapy after surgery remains uncertain. The analysis by Kim et al, based on National Cancer Database data, found no statistically significant survival benefit associated with chemotherapy in these patients. However, the results should not be hastily interpreted as evidence against chemotherapy altogether. Instead, clinicians must consider individualized treatment decisions based on pathological features and the patient’s overall health condition. This article further evaluated the strengths and weaknesses of Kim et al’s research design. It recommended conducting future studies, ideally prospective clinical trials or refined retrospective analyses, to better clarify chemotherapy’s role in this context.
